Shares of biotechnology company PepGen (NASDAQ:PEPG) are up in the pre-market session today after its lead candidate PGN-ED051 demonstrated promising results in a Phase 1 trial for treating Duchenne Muscular Dystrophy (DMD).
The drug showed high oligonucleotide delivery and exon skipping and was generally well tolerated. The company now plans to begin a Phase 2a trial in the first half of 2023.
Is PEPG Stock a Buy?
Analysts currently have a Strong Buy consensus rating on PEPG stock with an average price target of $27 which indicates a massive 227.27% potential upside for PepGen Stock.
Read full Disclosure